Cantor Fitzgerald Reiterates Neutral Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $220.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential downside of 22.13% from the company’s current price.

A number of other brokerages have also recently issued reports on ALNY. BMO Capital Markets restated an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Finally, Bank of America boosted their target price on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $282.05.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $3.89 during trading on Friday, hitting $282.51. The company had a trading volume of 247,691 shares, compared to its average volume of 864,664. The business’s 50-day moving average is $268.85 and its 200 day moving average is $210.78. The company has a market cap of $36.27 billion, a P/E ratio of -468.73 and a beta of 0.39. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the business posted ($2.21) earnings per share. The firm’s revenue was up 107.0% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals will post -2.73 EPS for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at $35,632. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $19,829,070. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,398 shares of company stock valued at $13,595,460. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALNY. V Square Quantitative Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $52,000. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the period. SteelPeak Wealth LLC raised its position in shares of Alnylam Pharmaceuticals by 147.7% during the 1st quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company’s stock worth $1,025,000 after buying an additional 4,090 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares during the period. Finally, Quattro Financial Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 2,517.8% in the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 4,809 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.